Title:
Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
A Phase 1a/1b Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
A Phase 1a/1b Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
A Phase 1a/1b Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation
Indication:
Breast Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
A Phase 1a/1b Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation
Indication:
Breast Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
Indication:
Lymphoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
Indication:
Lymphoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
Indication:
Lymphoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
Indication:
Lymphoma
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor
Indication:
Solid Tumors
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.
Indication:
Solid Tumors
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia
Indication:
Leukemia
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia
Indication:
Leukemia
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia
Indication:
Leukemia
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia
Indication:
Leukemia
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Colon Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Colon Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX
View
Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX
View
Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX
View
Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX
View
Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Colon Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Colon Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Gastric Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Gastric Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Gastric Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Gastric Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Liver Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Liver Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Liver Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Liver Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Liver Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Liver Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Liver Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Liver Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Liver Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Lung Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Lung Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Plano East
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Melanoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Melanoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Melanoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Melanoma
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Melanoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Melanoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Melanoma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Melanoma
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Mesothelioma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Mesothelioma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Mesothelioma
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Mesothelioma
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1 Dara r/r MM
View
Description: A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma (FT576-101)
Indication:
Myelomas
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
Ph1 Dara r/r MM
View
Description: A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma (FT576-101)
Indication:
Myelomas
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
Ph1 Dara r/r MM
View
Description: A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma (FT576-101)
Indication:
Myelomas
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors
View
Description: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1b TRK-950 Ovarian Peri & Fallopian
View
Description: A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Rectal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Rectal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Rectal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Rectal Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Rectal Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX
View
Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX
View
Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX
View
Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX
View
Description: AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Renal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Renal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Renal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Renal Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Renal Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Renal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Renal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Renal Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Renal Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Plano West
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Solid Tumors
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Urothelial Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Urothelial Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Gynecologic Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Urothelial Cancer
Location:
Texas Oncology-Baylor Charles A. Sammons Cancer Center Radiation Oncology
Phase: I
Title:
Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors
View
Description: JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors
Indication:
Urothelial Cancer
Location:
Texas Oncology-Waxahachie
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Plano West
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Allen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Medical City Dallas Building C
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Medical City Dallas Building D
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Medical City Dallas Radiation Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Methodist Dallas Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology–Methodist Dallas Cancer Center Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Presbyterian Cancer Center Dallas
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Denison Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Denton
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Flower Mound
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Flower Mound Gynecologic Oncology
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-McKinney
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Plano East
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Plano West
Phase: I